Pipeline
Designing the medicines of the future
At PharmEnable Therapeutics our mission is to develop innovative treatments for diseases with high unmet clinical need. With our scientist led, AI-enhanced approach, our aim is to create a drug discovery powerhouse with an asset-rich portfolio of next generation small molecule therapeutics.
Our pipeline
We are building an exciting pipeline of first- and best-in class small molecule therapeutics for unmet medical needs.
We focus on targets that cannot be addressed optimally by traditional small molecules.
Target
Therapeutic Area
Discovery
Optimisation
IND-enabling
Owner
Dual CDKs
Oncology
OX1
Neurology
CD73
Immunology
Kras
Oncology
Seeking partnering opportunities for all programmes and datasets.
Partner with us
Interested in finding out more about our exciting programmes?
| Target | Focus |
|---|---|
| Dual CDKs | Multi-active drug – dual intracellular inhibitor to overcome network redundancy |
| Target | Focus |
|---|---|
| Undisclosed (Neurology) | Selective targeting of a well-validated CNS receptor via a novel mechanism |
| Target | Focus |
|---|---|
| Undisclosed (oncology) | Overcome chemical space limitations to deliver first-in-class small molecule |
| Target | Focus |
|---|---|
| OX1 | Novel and selective antagonists overcoming ADME issues of known ligands |
| Target | Focus |
|---|---|
| CD73 | Novel, non-nucleotide inhibitors with favorable ADME properties |
| Target | Focus |
|---|---|
| Kras | Early dataset of small molecule binders targeted towards the SwitchII/a3 binding site with a view to develop pan-Kras activity whilst sparing other Ras isoforms. |